Articles | Country | Therapeutic centre | Inclusion criteria | Drugs | Age | Male percentage (%) | Dose | ITT population | Duration | ROCI % | HSSH % | mRS 0–1% | ACD % |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gotoh 2000 | Japan | 183 clinical institutes | Cerebral infarction at 1 to 6Â months | Cilostazol | 65.2 (NC) | 64.6 | 100Â mg twice daily | 533/1067 | 1-5 years | 5.7 | 0.8 | / | 1.7 |
Placebo | 65.1 (NC) | 60.8 | NC | 534/1067 | 10.8 | 1.3 | / | 1.9 | |||||
Huang 2008 | China | Multiple center trial | Cerebral infarction at 1 to 6Â months | Cilostazol | 60.14 (10.05) | 66.9 | NC | 360/719 | 1-1.5Â years | 3.1 | 0.3 | / | 0.8 |
Aspirin | 60.31 (9.71) | 70.5 | NC | 359/719 | 4.2 | 1.9 | / | 1.4 | |||||
Guo 2009 | China | Single center trail | Cerebral infarction at 1 to 6Â months | Cilostazol | 59.44 (10.63) | 35.3 | 100Â mg twice daily | 34/68 | 1Â year | 5.9 | 0 | / | 0 |
Aspirin | 62.06 (11.12) | 35.3 | 100 mgonce daily | 34/68 | 2.9 | 2.9 | / | 5.9 | |||||
Shinohara 2010 | Japan | 278 clinical institutes | Cerebral infarction in the previous 26 weeks | Cilostazol | 63.5 (9.2) | 71.7 | 100 mg twice daily | 1337/2672 | 1–5 years | 5.4 | 0.7 | / | 1.0 |
Aspirin | 63.4 (9.0) | 71.7 | 81Â mg once daily | 1335/2672 | 6.6 | 2.3 | / | 1.0 | |||||
Lee 2011 | Korea | 12 clinical institutes | Cerebral infarction within 48Â h of onset | Cilostazol | 63 (12) | 64.1 | 100Â mg twice daily | 231/458 | 90Â days | 2.2 | 0 | 56.3 | 0.4 |
Aspirin | 63 (12) | 58.6 | 300Â mg/day | 227/458 | 4.0 | 0.9 | 56.8 | 0 | |||||
Shimizu 2013 | Japan | 55 clinical institutes | Cerebral infarction within 48Â h of onset | Cilostazol | 66.2 (9.4) | 65.7 | 100Â mg twice daily | 251/507 | 90Â days | 1.2 | 0.8 | 74.5 | 0 |
Placebo | 66.6 (8.9) | 68.4 | NC | 256/507 | 1.6 | 0.8 | 72.7 | 0 |